Special drug use surveillance of Takecab tablets for "maintenance therapy of reflux esophagitis: long-term use"
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 11 Oct 2017
At a glance
- Drugs Vonoprazan (Primary)
- Indications Reflux oesophagitis
- Focus Adverse reactions
- Sponsors Takeda
- 06 Oct 2017 Planned number of patients changed from 1000 to 1237.
- 06 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 14 Jun 2016 New trial record